CO2024007192A2 - Moléculas de anticuerpo y conjugados - Google Patents
Moléculas de anticuerpo y conjugadosInfo
- Publication number
- CO2024007192A2 CO2024007192A2 CONC2024/0007192A CO2024007192A CO2024007192A2 CO 2024007192 A2 CO2024007192 A2 CO 2024007192A2 CO 2024007192 A CO2024007192 A CO 2024007192A CO 2024007192 A2 CO2024007192 A2 CO 2024007192A2
- Authority
- CO
- Colombia
- Prior art keywords
- antibody molecules
- conjugates
- egfr
- bind
- met
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163263835P | 2021-11-10 | 2021-11-10 | |
| PCT/EP2022/081225 WO2023083846A1 (en) | 2021-11-10 | 2022-11-09 | Antibody molecules and conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024007192A2 true CO2024007192A2 (es) | 2024-07-18 |
Family
ID=84387847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0007192A CO2024007192A2 (es) | 2021-11-10 | 2024-06-07 | Moléculas de anticuerpo y conjugados |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12065496B2 (https=) |
| EP (1) | EP4429765A1 (https=) |
| JP (1) | JP2024544520A (https=) |
| KR (1) | KR20240099430A (https=) |
| CN (1) | CN118556084A (https=) |
| AR (1) | AR127629A1 (https=) |
| CA (1) | CA3237211A1 (https=) |
| CL (1) | CL2024001384A1 (https=) |
| CO (1) | CO2024007192A2 (https=) |
| EC (1) | ECSP24044371A (https=) |
| IL (1) | IL312566A (https=) |
| MX (1) | MX2024005712A (https=) |
| TW (1) | TW202336037A (https=) |
| WO (1) | WO2023083846A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3259492A1 (en) * | 2022-06-27 | 2024-01-04 | Astrazeneca Ab | COMBINATIONS INVOLVING EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER |
| TW202527997A (zh) * | 2023-11-15 | 2025-07-16 | 大陸商四川科倫博泰生物醫藥股份有限公司 | 靶向ｅｇｆｒ／ｃ—ｍｅｔ之抗體—藥物結合物以及其製備方法及用途 |
| WO2025106278A1 (en) | 2023-11-17 | 2025-05-22 | Mersana Therapeutics, Inc. | Treatment of cancer using b7-h4-targeted antibody-drug conjugates |
| WO2025108427A1 (zh) * | 2023-11-23 | 2025-05-30 | 橙帆生物医药公司 | 结合分子及抗体药物偶联物和用途 |
| CN117659203B (zh) * | 2023-12-06 | 2024-08-13 | 科弈(浙江)药业科技有限公司 | 一种抗met/egfr双特异性抗体及其药物偶联物 |
| WO2025230409A1 (en) * | 2024-04-30 | 2025-11-06 | Merus N.V. | Multispecific antibody-drug conjugates |
| WO2025230410A1 (en) * | 2024-04-30 | 2025-11-06 | Merus N.V. | Multispecific antibody-drug conjugates |
| WO2026021476A1 (en) | 2024-07-24 | 2026-01-29 | Beone Guangzhou Biologics Manufacturing Co., Ltd. | Anti-cmet and anti-egfr multispecific antibody drug conjugates |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US7776814B2 (en) | 2002-07-09 | 2010-08-17 | R&D-Biopharmaceuticals Gmbh | Tubulysin conjugates |
| DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
| CL2008001334A1 (es) | 2007-05-08 | 2008-09-22 | Genentech Inc | Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer. |
| NZ584514A (en) | 2007-10-19 | 2012-07-27 | Genentech Inc | Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates |
| JP2013535220A (ja) | 2010-08-06 | 2013-09-12 | エンドサイト，インコーポレイテッド | ツブリシンを調製するためのプロセス |
| RS60499B1 (sr) | 2011-12-20 | 2020-08-31 | Medimmune Llc | Modifikovani polipeptidi za bispecifične skelete antitela |
| KR102089591B1 (ko) * | 2013-07-29 | 2020-03-18 | 삼성전자주식회사 | 항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체 |
| EA032203B1 (ru) | 2014-04-11 | 2019-04-30 | МЕДИММЬЮН ЭлЭлСи | Производные тубулизина |
| CN108350078A (zh) * | 2015-11-03 | 2018-07-31 | 默克专利股份公司 | 用于提高肿瘤选择性和抑制的双特异性抗体及其用途 |
| JP7325339B2 (ja) * | 2017-05-30 | 2023-08-14 | チョン クン ダン ファーマシューティカル コーポレーション | 新規な抗ｃ－Ｍｅｔ抗体およびその用途 |
-
2022
- 2022-11-09 US US18/053,955 patent/US12065496B2/en active Active
- 2022-11-09 EP EP22817545.1A patent/EP4429765A1/en active Pending
- 2022-11-09 CA CA3237211A patent/CA3237211A1/en active Pending
- 2022-11-09 KR KR1020247018705A patent/KR20240099430A/ko active Pending
- 2022-11-09 IL IL312566A patent/IL312566A/en unknown
- 2022-11-09 WO PCT/EP2022/081225 patent/WO2023083846A1/en not_active Ceased
- 2022-11-09 MX MX2024005712A patent/MX2024005712A/es unknown
- 2022-11-09 CN CN202280086269.9A patent/CN118556084A/zh active Pending
- 2022-11-09 JP JP2024527384A patent/JP2024544520A/ja active Pending
- 2022-11-10 AR ARP220103086A patent/AR127629A1/es unknown
- 2022-11-10 TW TW111143063A patent/TW202336037A/zh unknown
-
2024
- 2024-05-08 CL CL2024001384A patent/CL2024001384A1/es unknown
- 2024-06-07 EC ECSENADI202444371A patent/ECSP24044371A/es unknown
- 2024-06-07 CO CONC2024/0007192A patent/CO2024007192A2/es unknown
- 2024-06-25 US US18/753,316 patent/US20240360226A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240360226A1 (en) | 2024-10-31 |
| AU2022384597A1 (en) | 2024-06-13 |
| CA3237211A1 (en) | 2023-05-19 |
| EP4429765A1 (en) | 2024-09-18 |
| WO2023083846A1 (en) | 2023-05-19 |
| AR127629A1 (es) | 2024-02-14 |
| CN118556084A (zh) | 2024-08-27 |
| US12065496B2 (en) | 2024-08-20 |
| KR20240099430A (ko) | 2024-06-28 |
| JP2024544520A (ja) | 2024-12-03 |
| ECSP24044371A (es) | 2024-07-31 |
| MX2024005712A (es) | 2024-05-24 |
| US20230183358A1 (en) | 2023-06-15 |
| IL312566A (en) | 2024-07-01 |
| TW202336037A (zh) | 2023-09-16 |
| CL2024001384A1 (es) | 2024-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024007192A2 (es) | Moléculas de anticuerpo y conjugados | |
| DOP2020000032A (es) | Proteínas de unión específicas y sus usos | |
| CL2021002769A1 (es) | Anticuerpos de unión a vista (divisional solicitud n° 201902610) | |
| AR119295A1 (es) | Moléculas de unión a antígeno ligantes de cea | |
| ECSP19090538A (es) | Moléculas de anticuerpo que se unen a cd73 y usos de las mismas | |
| ECSP23025680A (es) | Moléculas de unión a b7-h4 terapéuticas | |
| AR114284A1 (es) | Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl | |
| MX2020008075A (es) | Anticuerpos anti-ctla4 y métodos para elaborarlos y usarlos. | |
| CL2020002410A1 (es) | Anticuerpos de unión a vista a ph ácido | |
| UY32915A (es) | Proteínas de únión específicas y sus usos | |
| MX2023008327A (es) | Anticuerpos inmunomoduladores de anticuerpo-farmaco. | |
| BR112016020065A2 (pt) | sítios específicos para modificar anticorpos para fazer imunoconjugados | |
| MX2010001757A (es) | Anticuerpo monoclonal 175 que activa el receptor egf y derivados y usos del mismo. | |
| UY35399A (es) | Conjugados de fármacos con anticuerpos | |
| UY39436A (es) | Proteínas de unión específicas y sus usos | |
| BR112022009672A2 (pt) | Tratamento de cânceres com conjugados anticorpo-fármaco (adc) que se ligam a proteínas 191p4d12 | |
| BR112019023909A8 (pt) | Uso de um imunoconjugado que se liga a folr1, e, uso de um imunoconjugado que se liga a folr1 e pembrolizumab | |
| MX2021000783A (es) | Anticuerpos humanizados contra psma. | |
| CO2023016712A2 (es) | Conjugados de neodegradador-anticuerpo anti-cd33 | |
| MX2023000732A (es) | Anticuerpos anti- alfa-4-beta-7. | |
| CO2026002111A2 (es) | Anticuerpos gucy2c y usos de estos | |
| CO2023017609A2 (es) | Anticuerpos multiespecíficos anti-cea y anti-cd137 y métodos de uso | |
| BR112015025549A2 (pt) | anticorpo contra o receptor do fator de crescimento epidérmico | |
| CO2025000447A2 (es) | Moléculas de unión al antígeno anti-steap1 y sus usos | |
| MX2021001604A (es) | Tratamiento del cáncer con un anticuerpo. |